HUP0303264A3 - Carbamate compounds for use in preventing and treating neurodegenerative disorders - Google Patents

Carbamate compounds for use in preventing and treating neurodegenerative disorders

Info

Publication number
HUP0303264A3
HUP0303264A3 HU0303264A HUP0303264A HUP0303264A3 HU P0303264 A3 HUP0303264 A3 HU P0303264A3 HU 0303264 A HU0303264 A HU 0303264A HU P0303264 A HUP0303264 A HU P0303264A HU P0303264 A3 HUP0303264 A3 HU P0303264A3
Authority
HU
Hungary
Prior art keywords
preventing
neurodegenerative disorders
treating neurodegenerative
carbamate compounds
carbamate
Prior art date
Application number
HU0303264A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HUP0303264A2 publication Critical patent/HUP0303264A2/hu
Publication of HUP0303264A3 publication Critical patent/HUP0303264A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
HU0303264A 2001-02-27 2002-02-21 Carbamate compounds for use in preventing and treating neurodegenerative disorders HUP0303264A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
PCT/US2002/005541 WO2002067925A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
HUP0303264A2 HUP0303264A2 (hu) 2004-01-28
HUP0303264A3 true HUP0303264A3 (en) 2012-07-30

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303264A HUP0303264A3 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing and treating neurodegenerative disorders

Country Status (26)

Country Link
US (3) US20020165273A1 (enExample)
EP (1) EP1383489B1 (enExample)
JP (1) JP4276840B2 (enExample)
KR (1) KR100910928B1 (enExample)
CN (1) CN1235579C (enExample)
AR (1) AR035756A1 (enExample)
AT (1) ATE361745T1 (enExample)
BR (1) BR0207645A (enExample)
CA (1) CA2439295C (enExample)
CY (1) CY1106753T1 (enExample)
CZ (1) CZ301203B6 (enExample)
DE (1) DE60220043T2 (enExample)
DK (1) DK1383489T3 (enExample)
ES (1) ES2284845T3 (enExample)
HU (1) HUP0303264A3 (enExample)
IL (2) IL157591A0 (enExample)
MX (1) MXPA03007718A (enExample)
MY (1) MY138156A (enExample)
NO (1) NO20033798L (enExample)
NZ (1) NZ527990A (enExample)
PL (1) PL364680A1 (enExample)
PT (1) PT1383489E (enExample)
RS (1) RS51055B (enExample)
RU (1) RU2300373C2 (enExample)
TW (1) TWI312679B (enExample)
WO (1) WO2002067925A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2580584C (en) * 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
ATE464044T1 (de) * 2004-09-16 2010-04-15 Janssen Pharmaceutica Nv Verwendung von 2-phenyl-1,2-ethanediol- (di)carbamaten zur behandlung von epileptogenese
KR20070085309A (ko) * 2004-10-15 2007-08-27 얀센 파마슈티카 엔.브이. 신경변성 질환 치료에 사용하는 카바메이트 화합물
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
CN101272776B (zh) * 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
CA2665573A1 (en) * 2006-10-06 2008-04-17 Janssen Pharmaceutica N.V. Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate
EP2081648A2 (en) * 2006-10-30 2009-07-29 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating depression
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
ES2711619T3 (es) * 2010-07-02 2019-05-06 Bio Pharm Solutions Co Ltd Compuesto carbamato de fenilo y relajante muscular que contiene dicho compuesto
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
WO2013100566A1 (en) 2011-12-27 2013-07-04 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same
CN109939092B (zh) * 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
CN110478343A (zh) 2013-03-12 2019-11-22 比皮艾思药物研发有限公司 氨基甲酸苯酯化合物和包含该化合物的用于预防或治疗神经性毒气引起的疾病的组合物
WO2017150903A1 (en) 2016-02-29 2017-09-08 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
ES3035674T3 (en) * 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
CA3112166A1 (en) * 2018-09-21 2020-03-26 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CA3191072A1 (en) 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
CN116234798A (zh) 2020-09-10 2023-06-06 生物药品解决方案有限公司 用于治疗或缓解精神疾病的氨基磺酸酯衍生物化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
ATE369130T1 (de) * 2001-02-27 2007-08-15 Ortho Mcneil Pharm Inc Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
ES2262801T3 (es) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato para la prevencion o el tratamiento de trastorno bipolar.
AU2002242296B2 (en) * 2001-02-27 2006-06-29 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders

Also Published As

Publication number Publication date
CN1503667A (zh) 2004-06-09
EP1383489B1 (en) 2007-05-09
JP4276840B2 (ja) 2009-06-10
PT1383489E (pt) 2007-06-21
JP2004523555A (ja) 2004-08-05
US20020165273A1 (en) 2002-11-07
ATE361745T1 (de) 2007-06-15
ES2284845T3 (es) 2007-11-16
CA2439295A1 (en) 2002-09-06
TWI312679B (en) 2009-08-01
IL157591A (en) 2009-12-24
US20040171679A1 (en) 2004-09-02
DK1383489T3 (da) 2007-08-06
RU2300373C2 (ru) 2007-06-10
NO20033798D0 (no) 2003-08-26
BR0207645A (pt) 2004-12-28
IL157591A0 (en) 2004-03-28
MXPA03007718A (es) 2004-11-12
EP1383489A1 (en) 2004-01-28
MY138156A (en) 2009-04-30
CN1235579C (zh) 2006-01-11
KR20030076714A (ko) 2003-09-26
CZ20032313A3 (cs) 2004-08-18
RS67403A (sr) 2006-12-15
HK1060516A1 (en) 2004-08-13
KR100910928B1 (ko) 2009-08-06
DE60220043D1 (de) 2007-06-21
WO2002067925A1 (en) 2002-09-06
PL364680A1 (en) 2004-12-13
CA2439295C (en) 2010-05-25
HUP0303264A2 (hu) 2004-01-28
AR035756A1 (es) 2004-07-07
CZ301203B6 (cs) 2009-12-09
NO20033798L (no) 2003-09-26
HK1065486A1 (en) 2005-02-25
US20090005442A1 (en) 2009-01-01
RS51055B (sr) 2010-10-31
NZ527990A (en) 2006-01-27
CY1106753T1 (el) 2012-05-23
DE60220043T2 (de) 2008-01-10
RU2003128982A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
HUP0303264A3 (en) Carbamate compounds for use in preventing and treating neurodegenerative disorders
HUP0303344A3 (en) Carbamate compounds for use in preventing and treating movement disorders
IL208191A0 (en) Compositions and methods for treating rage-associated disorders
IL233205B (en) Substances for the treatment or prevention of pre-eclampsia
EP1438020A4 (en) TOPICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
PT2311466E (pt) Compostos antimicrobianos e métodos para a sua utilização
EP1567198A4 (en) MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
GB2425617B (en) Device for preventing and treating myopia
HUS1300035I1 (hu) Dihidroimidazolonok alkalmazása epilepszia kezelésére kutyákban
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
HUP0303261A3 (en) Carbamate compounds for use in preventing or treating bipolar disorder
HUP0303243A3 (en) Carbamate compounds for use in preventing and treating bipolar disorder
IL157593A0 (en) Carbamate compounds for use in the treatment of pain
HUP0303342A3 (en) Carbamate compounds for use in preventing and treating psychotic disorders
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
GB0119025D0 (en) Compounds and their therapeutic use
AU2003278935A8 (en) Method and composition for treating neurodegenerative disorders
EP1425020A4 (en) METHOD AND COMPOSITIONS FOR TREATING APOPTOSIS-RELATED DISEASES
AU2003297259A8 (en) Methods and compositions for treating neurological disorders
ZA200307473B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders.
GB2376943B (en) Compounds and their therapeutic use
IL159846A0 (en) Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
ZA200307477B (en) Carbamate compounds for use in preventing or treating movement disorders.

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees